Investigational drug · Phase 2
Sapanisertib
Also called: FTH-003, MLN0128
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Endometrial Cancer, HR+ HER2- Breast Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
49
Any phase or sponsor naming "Sapanisertib"
First trial start
2024
Dec 12, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sapanisertib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Endometrial Cancer
- HR+ HER2- Breast Cancer
Approved drugs for the same conditions: Breast cancer · Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Sapanisertib" as an intervention, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial CancerPivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT02725268 · 241 participants · Start Apr 1, 2016 · Primary completion Jul 2, 2019
Drug: Paclitaxel; Sapanisertib and 1 more · For: Endometrial Neoplasms
Sites: Birmingham, Alabama; Phoenix, Arizona; Greenbrae, California · 78 sites in all
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01058707 · 198 participants · Start Jan 4, 2010 · Primary completion Feb 7, 2019
Drug: MLN0128 · For: Advanced Solid Malignancies
Sites: Scottsdale, Arizona; Los Angeles, California; Miami, Florida · 16 sites in all
- Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic SarcomaPivotal-lookingTerminated
National Cancer Institute (NCI)NIH
NCT02601209 · 151 participants · Start Nov 30, 2015 · Primary completion Dec 7, 2018
Drug: Pazopanib; Pazopanib Hydrochloride and 1 more · For: High Grade Sarcoma; Metastatic Leiomyosarcoma; Metastatic Malignant Peripheral Nerve Sheath Tumor and 16 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 460 sites in all
- Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor TherapyPivotal-lookingCompleted
Calithera Biosciences, IncIndustry
NCT02756364 · 141 participants · Start Jul 28, 2016 · Primary completion Nov 25, 2019
Drug: Fulvestrant; Sapanisertib · For: Breast Neoplasms
Sites: Mobile, Alabama; Bakersfield, California; Fullerton, California · 53 sites in all
- Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)Pivotal-lookingCompleted
Imperial College LondonAcademic, hospital or other
NCT03648489 · 134 participants · Start Sep 21, 2018 · Primary completion Nov 30, 2023
Drug: Paclitaxel; TAK228 · For: Ovarian Cancer; Ovarian Neoplasms; Ovarian Carcinosarcoma and 7 more
Sites: Berlin, Germany; Dresden, Germany; Essen, Germany · 15 sites in all
Calithera Biosciences, IncIndustry
NCT02049957 · 118 participants · Start Feb 13, 2014 · Primary completion Jun 29, 2018
Drug: Sapanisertib; Fulvestrant and 1 more · For: Breast Cancer
Sites: Los Angeles, California; San Francisco, California; Santa Barbara, California · 40 sites in all
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01899053 · 101 participants · Start Jun 28, 2013 · Primary completion Jan 31, 2017
Drug: TAK-228; TAK-117 · For: Advanced Nonhematologic Malignancies
Sites: Boston, Massachusetts; Nashville, Tennessee; San Antonio, Texas · 5 sites in all
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT02724020 · 96 participants · Start Jun 30, 2016 · Primary completion Feb 3, 2020
Drug: Everolimus; MLN0128 and 1 more · For: Clear-cell Metastatic Renal Cell Carcinoma
Sites: Los Angeles, California; Venice, Florida; West Palm Beach, Florida · 36 sites in all
National Cancer Institute (NCI)NIH
NCT06811116 · 92 participants (planned) · Start Nov 17, 2025 · Primary completion Aug 31, 2027
Drug: Cabozantinib S-malate; Sapanisertib · For: Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma; Stage III Hepatocellular Carcinoma AJCC v8 and 1 more
Sites: Irvine, California; Orange, California; Portland, Oregon · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Rapalink-1 reveals an mTOR- and p53-regulated transcriptional program in Neuro-2a cells.
Nyarkoh JK, Wolan M, Barrett E, et al. · Biol Open 2026
- Genome-wide copy number analysis identifies AKT as a novel therapeutic target in pleural mesothelioma.
Kalla C, Mönch D, Steinlein S, et al. · Lung Cancer 2026
- A dataset supporting Combinatorial Proteome Integral Solubility/Stability Alteration Analysis (CoPISA).
Zangene E, Gholizadeh E, Vadadokhau U, et al. · Sci Data 2026
- Targeting the 4EBP1/HSP90β/Nrf2 Axis Sensitizes β-catenin-mutant Hepatocellular Carcinoma to mTOR Inhibitors via Ferroptosis Induction.
Li R, Zhou Y, Wang Z, et al. · J Clin Transl Hepatol 2026
- Spatially resolved ex vivo drug response profiling in SMARCB1-deficient sinonasal carcinoma.
Jurmeister P, Flach S, Bergmayr L, et al. · EMBO Mol Med 2026
- mTOR inhibition enhances the antitumor efficacy of pan-RAF-MEK blockade by inhibiting the ATF4-MTHFD2 pathway.
Cai F, Huang F, Goncalves C, et al. · Cell Death Dis 2026
Also in development for Endometrial Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- Rina-SPRO1184, GEN1184Phase 39 trials
Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer
- DB-1303BNT323, trastuzumab pamirtecanPhase 35 trials
DualityBio Inc. · Metastatic Breast Cancer, HER2-positive Advanced Solid Tumor, Endometrial Cancer
- AZD5335Torvutatug samrotecan, Torvu-samPhase 34 trials
AstraZeneca · Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.